Status:
COMPLETED
Intravenous Immunoglobulin (IVIG) in Lung Transplantation
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Grifols Therapeutics LLC
Conditions:
Hypogammaglobulinemia
Lung Transplantation
Eligibility:
All Genders
12-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
Detailed Description
An increased risk of infection despite intensive antimicrobial prophylaxis is a well-recognized complication of lung transplantation. Recent evidence suggests that immunosuppressive therapy after soli...
Eligibility Criteria
Inclusion
- Lung transplant recipients \> 3 months after transplant surgery
- Immunoglobulin G (IgG) \< 500 mg/dL
- Stable medical regimen
Exclusion
- Acute rejection
- Active infection
- Contraindication to IVIG
- Pregnancy
- Recent thrombotic event
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00115778
Start Date
June 1 2005
End Date
August 1 2010
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Hospital Lung Transplant Program
New York, New York, United States, 10032